2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Circulation, Journal Year: 2024, Volume and Issue: 149(8)

Published: Jan. 24, 2024

BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, obesity) factors (cholesterol, blood pressure, glucose control, metabolic syndrome) that contribute health. AHA Disease Stroke Statistical Update presents latest data on a range major clinical circulatory disease conditions (including brain health, complications pregnancy, kidney congenital rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary cardiomyopathy, failure, valvular venous thromboembolism, peripheral artery disease) associated outcomes quality care, procedures, economic costs). METHODS: AHA, through its Epidemiology Prevention Statistics Committee, continuously monitors evaluates sources stroke United States globally provide current information available annual review published literature year before writing. 2024 is product full year’s worth effort 2023 by dedicated volunteer clinicians scientists, committed government professionals, staff members. strives further understand help heal problems inflicted structural racism, public crisis can significantly damage mental perpetuate disparities access education, income, housing, several other vital healthy lives. This edition includes additional global data, as well monitoring benefits population, an enhanced focus equity across key domains. RESULTS: Each chapters focuses different topic statistics. CONCLUSIONS: represents critical resource for lay public, policymakers, media clinicians, care administrators, researchers, advocates, others seeking best these conditions.

Language: Английский

---

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Circulation, Journal Year: 2023, Volume and Issue: 148(9)

Published: July 20, 2023

AIM: The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease” provides an update to and consolidates new evidence since “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Diagnosis Stable Ischemic Heart corresponding “2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update Disease.” METHODS: A comprehensive literature search was conducted from September 2021 May 2022. Clinical studies, systematic reviews meta-analyses, other on human participants were identified that published in English MEDLINE (through PubMed), EMBASE, Cochrane Library, Agency Healthcare Research Quality, selected databases relevant this guideline. STRUCTURE: This guideline evidenced-based patient-centered approach management patients with chronic coronary disease, considering social determinants health incorporating principles shared decision-making team-based care. Relevant topics include general approaches treatment decisions, guideline-directed therapy reduce symptoms future cardiovascular events, pertaining revascularization recommendations special populations, patient follow-up monitoring, gaps, areas need research. Where applicable, based availability cost-effectiveness data, cost–value are also provided clinicians. Many previously guidelines have been updated evidence, created when supported by data.

Language: Английский

---

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

The Lancet, Journal Year: 2023, Volume and Issue: 401(10384), P. 1293 - 1301

Published: March 6, 2023

Language: Английский

---

A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association

Circulation, Journal Year: 2023, Volume and Issue: 148(20), P. 1636 - 1664

Published: Oct. 9, 2023

A growing appreciation of the pathophysiological interrelatedness metabolic risk factors such as obesity and diabetes, chronic kidney disease, cardiovascular disease has led to conceptualization cardiovascular-kidney-metabolic syndrome. The confluence within syndrome is strongly linked for adverse outcomes. In addition, there are unique management considerations individuals with established coexisting factors, or both. An extensive body literature supports our scientific understanding of, approach to, prevention However, critical gaps in knowledge related terms mechanisms development, heterogeneity clinical phenotypes, interplay between social determinants health biological accurate assessments incidence context competing risks. There also key limitations data supporting care syndrome, particularly early-life prevention, screening interdisciplinary models, optimal strategies lifestyle modification weight loss, targeting emerging cardioprotective kidney-protective therapies, patients both impact systematically assessing addressing health. This statement uses a crosswalk major guidelines, addition review literature, summarize evidence fundamental science, screening,

Language: Английский

---

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease

Journal of the American College of Cardiology, Journal Year: 2023, Volume and Issue: 82(9), P. 833 - 955

Published: July 20, 2023

Language: Английский

---

American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update

Endocrine Practice, Journal Year: 2023, Volume and Issue: 29(5), P. 305 - 340

Published: May 1, 2023

Language: Английский

---

Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

Journal of Atherosclerosis and Thrombosis, Journal Year: 2023, Volume and Issue: 31(6), P. 641 - 853

Published: Dec. 18, 2023

Language: Английский

---

Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality

European Heart Journal, Journal Year: 2023, Volume and Issue: 44(16), P. 1432 - 1445

Published: Jan. 12, 2023

Abstract Aims Cholesterol carried in triglyceride-rich lipoproteins, also called remnant cholesterol, is being increasingly acknowledged as an important causal risk factor for atherosclerosis. Elevated marked by elevated plasma triglycerides, associated causally with increased of atherosclerotic cardiovascular disease. The association cause-specific mortality is, however, unclear. aim this study was to test the hypothesis that cholesterol and triglycerides are from disease, cancer, other causes. Methods results Using a contemporary population-based cohort, 87 192 individuals Copenhagen General Population Study aged 20–69 years at baseline 2003–2015 were included. During up 13 follow-up, 687 died 1594 856 causes, according National Danish Causes Death Registry. In ≥1.0 mmol/L (≥39 mg/dL; 22% population) compared those levels <0.5 (<19 mg/dL), multivariable-adjusted hazard ratios 2.2 (95% confidence interval 1.3–3.5) 1.0 (0.7–1.3) 2.1 (1.4–3.3) Exploratory analysis cause death subcategories showed corresponding 4.4 (1.6–11) ischemic heart 8.4 (2.0–34) infectious diseases, 9.1 (1.9–43) endocrinological diseases. Results >2 vs. <1 (>177 <89 mg/dL) similar. Conclusion Remnant ≥1 (39 present population, ≥2 (177 28% two-fold but not cancer. This novel finding should be confirmed cohorts.

Language: Английский

---

Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society

European Heart Journal, Journal Year: 2023, Volume and Issue: 44(39), P. 4157 - 4173

Published: Aug. 23, 2023

Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular (ASCVD). Despite progress during last 30 years, ASCVD mortality now increasing, fastest relative increase middle-aged women. Missed or delayed diagnosis undertreatment do not fully explain this burden disease. Sex-specific factors, such as hypertensive disorders pregnancy, premature menopause (especially primary ovarian insufficiency), polycystic ovary syndrome are also relevant, good evidence that these associated greater risk. This position statement from European Atherosclerosis Society focuses on well sex-specific effects lipids, including lipoprotein(a), over life course which impact Women disproportionately impacted (in terms) by diabetes, chronic kidney disease, auto-immune inflammatory All compounded sociocultural components related gender. panel stresses need identify treat modifiable risk factors earlier women, especially for those at conditions, reduce unacceptably high

Language: Английский

---

Genetic association of lipids and lipid-lowering drug target genes with non-alcoholic fatty liver disease

EBioMedicine, Journal Year: 2023, Volume and Issue: 90, P. 104543 - 104543

Published: March 30, 2023

Some observational studies found that dyslipidaemia is a risk factor for non-alcoholic fatty liver disease (NAFLD), and lipid-lowering drugs may lower NAFLD risk. However, it remains unclear whether causative NAFLD. This Mendelian randomisation (MR) study aimed to explore the causal role of lipid traits in evaluate potential effect drug targets on NAFLD.Genetic variants associated with genes encoding were extracted from Global Lipids Genetics Consortium genome-wide association (GWAS). Summary statistics obtained two independent GWAS datasets. Lipid-lowering reached significance further tested using expression quantitative trait loci data relevant tissues. Colocalisation mediation analyses performed validate robustness results mediators.No significant eight was found. Genetic mimicry lipoprotein lipase (LPL) enhancement risks datasets (OR1 = 0.60 [95% CI 0.50-0.72], p1 2.07 × 10-8; OR2 0.57 0.39-0.82], p2 3.00 10-3). A MR (OR 0.71 CI, 0.58-0.87], p 1.20 10-3) strong colocalisation (PP.H4 0.85) observed LPL subcutaneous adipose tissue. Fasting insulin type 2 diabetes mediated 7.40% 9.15%, respectively, total risk.Our findings do not support as Among nine targets, promising candidate target The mechanism action be its effects.Capital's Funds Health Improvement Research (2022-4-4037). CAMS Innovation Fund Medical Sciences (CIFMS, grant number: 2021-I2M-C&T-A-010).

Language: Английский

---